Skip to content
10-Q

Quarterly Report

Titan Pharmaceuticals, Inc.

0001829126-25-003656

← back to feed
Filed
May 14, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 12, 2025 914.23K sh
Shares Diluted Q1 2025 · Mar 31, 2025 914K sh
Shares Diluted Q1 2025 · Mar 31, 2024 853K sh
Operating Cash Flow Q1 2025 · Mar 31, 2025 −$867K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$613K
Cash And Equivalents Q1 2025 · Mar 31, 2025 $1.95M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $2.83M
Stockholders Equity Q1 2025 · Mar 31, 2025 $1.88M
Stockholders Equity Q1 2025 · Dec 31, 2024 $2.44M
Stockholders Equity Q1 2025 · Mar 31, 2024 $6.09M
Stockholders Equity Q1 2025 · Dec 31, 2023 $6.64M
Current Liabilities Q1 2025 · Mar 31, 2025 $279K
Current Liabilities Q1 2025 · Dec 31, 2024 $483K
Total Liabilities Q1 2025 · Mar 31, 2025 $279K
Total Liabilities Q1 2025 · Dec 31, 2024 $483K
Current Assets Q1 2025 · Mar 31, 2025 $2.16M
Current Assets Q1 2025 · Dec 31, 2024 $2.92M
Total Assets Q1 2025 · Mar 31, 2025 $2.16M
Total Assets Q1 2025 · Dec 31, 2024 $2.92M
Eps Diluted Q1 2025 · Mar 31, 2025 −$0.62
Eps Diluted Q1 2025 · Mar 31, 2024 −$1.24
Eps Basic Q1 2025 · Mar 31, 2025 −$0.62
Eps Basic Q1 2025 · Mar 31, 2024 −$1.24
Net Income Q1 2025 · Mar 31, 2025 −$563K
Net Income Q1 2025 · Mar 31, 2024 −$1.06M
Operating Income Q1 2025 · Mar 31, 2025 −$534K
Operating Income Q1 2025 · Mar 31, 2024 −$1.06M